Phase Forward and Quintiles CelebrateElectronic Data Capture Milestone

Quintiles Launches 400th Electronic Data Capture TrialUsing Phase Forward`s
InForm Software
WALTHAM, Mass.--(Business Wire)--
Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions
for clinical trials and drug safety, today announced that Quintiles
Transnational Corp., the world`s largest pharmaceutical services company, has
leveraged the InForm electronic data capture (EDC) solution for its 400th EDC
trial.

Since the two companies started working together in 1999, Quintiles has used the
InForm product in the majority of its EDC trials. To date, Quintiles has
initiated trials using InForm software on behalf of more than 90 customers
across all trial phases, spanning more than 27,000 sites in over 60 countries.

"We conduct regular surveys of our users to ensure that we are meeting their
expectations for performance and responsiveness," said Paula Stafford Brown,
executive vice president, Integrated Clinical Services, Quintiles. "As the
world`s leading CRO, Quintiles uses a number of EDC tools. Our surveys indicate
that clinical sites using InForm report a highly positive experience with the
product."

"Our shared success with Quintiles reflects the common strengths of our two
like-minded companies," said Bob Weiler, chairman and CEO, Phase Forward. "Both
firms are committed to providing leading solutions and the highest levels of
customer satisfaction for organizations small and large alike. Together, we are
supporting increasingly complex, diverse trials across multiple geographies."

About Quintiles

Quintiles Transnational Corp. helps bring new medicines to market and peak sales
faster by providing innovative, high-quality development, financial and
commercialization solutions to the pharmaceutical and biotechnology industries.
With more than 22,000 employees and offices in more than 50 countries, Quintiles
is focused on providing customer-centric solutions that are the gold standard of
the industry. For more information, please visit the company`s Web site at
www.quintiles.com.

About Phase Forward

Phase Forward is a leading provider of integrated data management solutions for
clinical trials and drug safety. The company offers proven solutions for
electronic data capture (InForm), phase I clinic automation (LabPas), clinical
data management (Clintrial), clinical trials signal detection (CTSD), strategic
pharmacovigilance (Empirica Signal) and Signal Management, adverse event
reporting (Empirica Trace), applied data standards (WebSDM), Web-integrated
interactive response technologies (Clarix), and clinical data analysis and
reporting automation and compliance (Waban SCE/CDR, Waban SMS and Waban LIMS).
In addition, the company provides services in the areas of application
implementation, hosting and validation, data integration, business process
optimization, safety data management and industry standards. Phase Forward`s
products and services have been utilized in over 10,000 clinical trials
involving more than 1,000,000 clinical trial study participants at over 280
organizations and regulatory agencies worldwide including: AstraZeneca, Boston
Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug
Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck
Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble,
Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, Tibotec
and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional
information about Phase Forward is available at www.phaseforward.com.

Cautionary Statement

Certain statements made in this press release that are not based on historical
information are forward-looking statements which are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995. This
press release contains express or implied forward-looking statements relating
to, among other things, the performance and features of Phase Forward`s products
and services, demand for Phase Forward`s products and services, future business
and operations plans of a Phase Forward customer, and the ability of Phase
Forward`s customers to realize benefits from the use of Phase Forward`s products
and services. These statements are neither promises nor guarantees, but are
subject to a variety of risks and uncertainties, many of which are beyond Phase
Forward's control, which could cause actual results to differ materially from
those contemplated in these forward-looking statements. In particular, the risks
and uncertainties include, among other things, the ability of Phase Forward`s
customers to realize benefits from the use of its products and services, the
possibility that customers` needs or plans may change over time, the possibility
that the level of demand for Phase Forward`s products and services may vary,
regulatory changes and competition. Existing and prospective investors are
cautioned not to place undue reliance on these forward-looking statements, which
speak only as of the date hereof. Phase Forward undertakes no obligation to
update or revise the information contained in this press release, whether as a
result of new information, future events or circumstances or otherwise. For
additional disclosure regarding these and other risks faced by Phase Forward,
see the disclosure contained in Phase Forward's public filings with the
Securities and Exchange Commission including, without limitation, its most
recent Annual Report on Form 10-K.

Phase Forward
Elaine Maynard, 781-902-4371
elaine.maynard@phaseforward.com
or
CHEN PR, Inc.
Randy Wambold, 781-672-3119
rwambold@chenpr.com

Copyright Business Wire 2009